Topiramate (Eprontia) vs Topiramate (Qudexy XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline

Topiramate (Eprontia)

Marketed by Azurity Pharmaceuticals

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Topiramate (Qudexy XR)

Marketed by Upsher-Smith Laboratories, LLC

Approved in Epilepsysmall molecule
Reliable signal

NCT01142193 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 249 participants. The primary clinical endpoint—percent reduction in weekly partial-onset seizure frequency over 11 weeks—was met, with a statistically significant advantage for USL255 over placebo (p<0.001).

Reported efficacy

Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) (met)

Result source: NCT01142193

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTopiramate (Eprontia)Topiramate (Qudexy XR)
Seizure frequency, % change—Not reported—Not posted · NCT00236717
50% responder rate—Not reported33.9% vs 17.6%+16.3 vs placebowk 3 · n 124NCT01142193
Seizure freedom—Not reported—Not posted · NCT00236717

Seizure frequency, % change

Topiramate (Eprontia)
—Not reported
Topiramate (Qudexy XR)
—Not posted · NCT00236717

50% responder rate

Topiramate (Eprontia)
—Not reported
Topiramate (Qudexy XR)
33.9% vs 17.6%+16.3 vs placebowk 3 · n 124NCT01142193

Seizure freedom

Topiramate (Eprontia)
—Not reported
Topiramate (Qudexy XR)
—Not posted · NCT00236717
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Topiramate (Eprontia): no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Topiramate (Eprontia): 0 of 4 rows · Topiramate (Qudexy XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTopiramate (Qudexy XR)
Dropout rate
16.9%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Discontinued due to AEs
9.7%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Serious AEs
1.6%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Most frequent reported AEs
somnolence 12.1% (placebo 2.4%)
dizziness 7.3% (placebo 5.6%)
paraesthesia 6.5% (placebo 2.4%)
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Topiramate (Qudexy XR)

Seizure 50 37.9% (n=124) vs 23.2% (n=125) placebo @ 11wk
responder rate · % of participants
Maintenance
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 1 more result
44.2% (n=113) vs 30.8% (n=120) placebo @ 8wk
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Seizure 50 33.9% (n=124) vs 17.6% (n=125) placebo @ 3wk
responder rate · % of participants
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3

Focal Onset Seizures

Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Focal Onset Seizures pipeline

Topiramate (Eprontia)

Marketed by Azurity Pharmaceuticals

Approved in Focal Onset Seizuressmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Topiramate (Qudexy XR)

Marketed by Upsher-Smith Laboratories, LLC

Approved in Focal Onset Seizuressmall molecule
Reliable signal

NCT01142193 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 249 participants. The primary clinical endpoint—percent reduction in weekly partial-onset seizure frequency over 11 weeks—was met, with a statistically significant advantage for USL255 over placebo (p<0.001).

Reported efficacy

Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) (met)

Result source: NCT01142193

Results for Focal Onset Seizures

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Topiramate (Eprontia): no structured comparison results are available for Focal Onset Seizures.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Topiramate (Qudexy XR)

Seizure 50 37.9% (n=124) vs 23.2% (n=125) placebo @ 11wk
responder rate · % of participants
Maintenance
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 1 more result
44.2% (n=113) vs 30.8% (n=120) placebo @ 8wk
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Seizure 50 33.9% (n=124) vs 17.6% (n=125) placebo @ 3wk
responder rate · % of participants
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Available safety results

Topiramate (Qudexy XR)

Dropout rate
16.9%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Discontinued due to AEs
9.7%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Serious AEs
1.6%
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Most frequent reported AEs
somnolence 12.1% (placebo 2.4%)
dizziness 7.3% (placebo 5.6%)
paraesthesia 6.5% (placebo 2.4%)
NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Eprontia)'s landscape · Topiramate (Qudexy XR)'s landscape